ClinicalTrials.gg
RecruitingNCT07204418Updated Oct 13, 2026

A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants

A Phase 1 interventional study of Xanomeline/ Trospium Chloride in Healthy Volunteers, sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 13, 2026Study contact changed2 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the pharmacokinetics (PK) of xanomeline following administration of KarXT in CYP2D6 normal/extensive, intermediate, poor, and ultrarapid metabolizers.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy volunteer
  • Pharmacokinetics
  • BMS-986510
  • KarXT
  • Cobenfy
  • CYP2D6
03

In context

Lead sponsor

Karuna Therapeutics, Inc., a Bristol Myers Squibb company is the lead sponsor of 17 studies on the registry; 8 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

First submitted after Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be healthy male and female (INOCBP) participants as determined by no deviation from normal in medical history, physical examination, 12-lead (ECG), vital signs (VS), and clinical laboratory determinations.
  • Participant must be a normal/extensive, intermediate, poor, or ultrarapid CYP2D6 metabolizer.
  • Participant must have (BMI) of 18.0 to 32.0 kg/m2, inclusive.

Exclusion criteria

Exclusion Criteria:

  • Participants must not have evidence of organ dysfunction or any deviation from normal in physical examination, vital signs, 12-lead , or clinical laboratory determinations beyond what is consistent with the target population reference ranges.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    KarXT

    Drug: Xanomeline/ Trospium Chloride

Interventions

  • DrugXanomeline/ Trospium Chloride

    Drug pages: Xanomeline · Trospium chloride

    Specified dose on specified days

    Also known as: BMS-986510, KarXT

06

What researchers measure

Primary outcomes

  1. Geometric mean ratio for the area under the concentration-time curve from time zero to 12 hours post morning dose (AUC(0-12))

    Time frame: Up to Day 17

Secondary outcomes

  1. Number of participants with Adverse Events (AEs)

    Time frame: Up to 28 days post last dose

  2. Number of participants with Serious Adverse Events (SAEs)

    Time frame: Up to 28 days post last dose

  3. Number of participants with physical examination abnormalities

    Time frame: Up to 28 days post last dose

  4. Number of participants with vital sign abnormalities

    Time frame: Up to 28 days post last dose

  5. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to 28 days post last dose

  6. Number of participants with clinical laboratory test abnormalities

    Time frame: Up to 28 days post last dose

  7. Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to 28 days post last dose

  8. Number of participants with AEs of Special Interest (AESIs)

    Time frame: Up to 28 days post last dose

07

Study locations

1 of 3 sites recruiting
  • Local Institution - 0003
    Anaheim, California 92801, United States
    Completed

    Not enrolling at this site.

  • ICON - Lenexa
    Lenexa, Kansas 66219-9746, United States
    Recruiting
    • Patrick Yao, Site 0002 · Contact913-410-2674
  • Local Institution - 0001
    San Antonio, Texas 78209, United States
    Completed

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Oct 2, 2025
StartActual
Oct 13, 2025
Primary completionEst.
Dec 3, 2026
CompletionEst.
Dec 3, 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 United States)
  • Local Institution - 0003 · Anaheim, United States
  • Local Institution - 0001 · San Antonio, United States
Show 2 removed
  • Anaheim Clinical Trials · Anaheim, United States
  • ICON Development Solutions · San Antonio, United States
Oct 13, 2026
Contact
Study contact changed: person changed (no phone or email listed). See the current contact
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 United States)
    • Local Institution - 0003 · Anaheim, United States
    • Local Institution - 0001 · San Antonio, United States
    Show 2 removed
    • Anaheim Clinical Trials · Anaheim, United States
    • ICON Development Solutions · San Antonio, United States
    Contact Study contact changed: person changed (no phone or email listed). See the current contact
    + 2 other changes: verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07204418
Responsible party
Sponsor
First posted
Oct 2, 2025
Start date
Oct 13, 2025
Primary completion
Dec 3, 2026 (estimated)
Completion
Dec 3, 2026 (estimated)
Last update
Oct 13, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium chloride

Start the discussion